Certified Global Research Member
Key Questions Answered
- Global Market Outlook
- In-depth analysis of global and regional trends
- Analyze and identify the major players in the market, their market share, key developments, etc.
- To understand the capability of the major players based on products offered, financials, and strategies.
- Identify disrupting products, companies, and trends.
- To identify opportunities in the market.
- Analyze the key challenges in the market.
- Analyze the regional penetration of players, products, and services in the market.
- Comparison of major players’ financial performance.
- Evaluate strategies adopted by major players.
- Recommendations
Why Choose Market Research Future?
- Vigorous research methodologies for specific market.
- Knowledge partners across the globe
- Large network of partner consultants.
- Ever-increasing/ Escalating data base with quarterly monitoring of various markets
- Trusted by fortune 500 companies/startups/ universities/organizations
- Large database of 5000+ markets reports.
- Effective and prompt pre- and post-sales support.
Diagnostic advances, public awareness, and international hepatitis activities drive market growth. Healthcare practitioners, diagnostic labs, and industry players must understand these market trends to create effective hepatitis screening and diagnosis procedures.
The global effect of hepatitis B and C affects the market. Due to their high incidence and potential for serious liver consequences, these infections need accessible and accurate hepatitis test methods for prompt management and diagnosis.
Technical advances in hepatitis diagnosis are affecting the field. Progress in nucleic acid, serological, and point-of-care testing has led to faster, more accurate, and specific results. These advances improve screening and diagnosis in many healthcare settings.
Point-of-care hepatitis tests are growing in relevance. Rapid diagnostic tests that may be performed at the patient's bedside facilitate fast decision-making, especially in resource-constrained settings. This is consistent with worldwide efforts to increase hepatitis testing availability and reduce processing delays.
Public health efforts and screening programs drive the hepatitis test solution diagnostic industry. Governments and healthcare organizations worldwide are launching screening efforts to identify at-risk persons, increase awareness, and encourage early identification of hepatitis.
Improved molecular diagnoses in hepatitis testing solutions. High-sensitivity PCR identifies viral genetic material. These technologies enhance hepatitis diagnosis, viral load monitoring, and treatment.
The COVID-19 epidemic has boosted hepatitis testing. With the growing awareness of viral diseases' far-reaching effects, hepatitis testing has increased alongside COVID-19 testing. This dual testing strategy recognizes the need of complete health examinations.
Early diagnosis and treatment are prioritized in hepatitis testing programs. Every effort is made to quickly connect hepatitis patients to appropriate medical care, such as antiviral medicine and support services.
Hepatitis C genotype testing is growing. To enhance therapeutic results, predict treatment response, and adjust treatment regimens, hepatitis C viral genotype must be determined. This development reflects the growing importance of individualized hepatitis therapy.
Market-wide, HBsAg testing advancements matter. Hepatitis B diagnosis is improved by new assays and platforms that detect HBsAg, a key indication. Comprehensive screening programs need these advances.
International partnerships are advancing hepatitis efforts. Governments, non-profits, and the WHO are working together to improve diagnostics, extend hepatitis treatment, and adopt testing measures.
Data management and digitalization are being added to hepatitis testing programs. Digital systems enhance hepatitis treatment and diagnostic coordination by improving testing results, data analytics, and patient management.
Quality assurance and regulatory compliance are crucial in the hepatitis test solution diagnostic industry. Diagnostic test manufacturers spend in research, development, and validation to fulfill regulatory criteria and ensure test findings are reliable and precise.
Hepatitis Test Solution Diagnosis Market Highlights:
Global Hepatitis Diagnostic Test Solution Market Overview
The Hepatitis Diagnostic Test Solution Market Size was valued at USD 3.57 Billion in 2023.
The global Hepatitis Diagnostic Test Solution industry is projected to grow from USD 3.87 Billion in 2024 to USD 6.77 Billion by 2032, exhibiting a CAGR of 6.42% during the forecast period (2024 - 2032).
Quest Diagnostics, Inc. is a diagnostic testing organization as of July 2023. Recently, DGX revised their documentation regarding Alzheimer's disease and Hepatitis C tests. The organization published a report authored by CDC experts and utilizing data from the Quest Diagnostics Health Trends research program in order to bolster public health policy concerning HIV, hepatitis, COVID-19, and various other diseases. With the most recent introduction, Quest Diagnostics will enhance the Diagnostic Solutions division by expanding its range of testing services. DGX is dedicated to the advancement of state-of-the-art laboratory assays that assist in the evaluation of patients' susceptibility to dementia and other degenerative disorders. It is for the first time offering patients and clinicians across the nation access to cutting-edge laboratory technology for Alzheimer's disease via its AD-Detect collection of blood tests.
The Elecsys HCV Duo, which permits simultaneous and independent determination of hepatitis C virus (HCV) antigen and antibody status from a single human plasma or serum sample, is the first entirely automated immunoassay commercially available in India as of July 2023. This suggests that the test has the potential to identify infection even during its nascent phases, while the patient is recovering from the virus, or even in the presence of chronic illness. Viral hepatitis is progressively gaining recognition as a significant public health concern in India.
The number of HCV carriers is estimated to be between 12 and 13 million, and predictive models suggest that the disease burden will experience a substantial increase in the near future. Paradoxically, a mere 30% of individuals diagnosed with chronic HCV infection initiate therapy, while a mere 19% are cognizant of their diagnosis. Individuals who are in the early stages of the illness are unaware of their medical condition. Consequently, a substantial disparity exists between the time of diagnosis and the initiation of treatment.
Globally, there are approximately 71 million individuals that are chronically infected with the hepatitis C virus (HCV). The increasing participation of the regulatory agencies and health care associations towards the testing/diagnosis and treatments of the hepatitis is driving the global market. In 2018, the American Association for the Study of Liver Diseases and the Infectious Diseases Society of America, published a guideline for testing, managing, and treating hepatitis C. Various other factors such as the rise prevalence hepatitis, increasing geriatric population, rise in regulatory approvals, and growing participation of generic drugs manufacturers are boosting the market growth.
However, complicated testing and diagnosis process and the side-effects of medication may hamper market growth over the forecast period.
Hepatitis Diagnostic Test Solution Market Segment Insights
Hepatitis Diagnostic Test Solution Market is segmented based on disease type, type of technology, end user, and region.
Hepatitis Diagnostic Test Solution Type Insights
Based on disease type, the Hepatitis Diagnostic Test Solution market is further segmented into hepatitis A, hepatitis B, hepatitis C, and others.
Hepatitis Diagnostic Test Solution Technology Insights
Based on the type of technology, the Hepatitis Diagnostic Test Solution industry at the global level is segmented into nucleic acid testing (NAT), enzyme-linked immunosorbent assay (ELISA), rapid diagnostic tests (RDT), chemiluminescence immunoassay (CLIA), genotyping, and others.
Hepatitis Diagnostic Test Solution End User Insights
Based on end-user, the global market is segmented into hospitals, clinics, diagnostic laboratories, blood banks, research institutes, and others
Hepatitis Diagnostic Test Solution Regional Insights
The segments mentioned above are covered under four regions, namely, the Americas, Europe, Asia-Pacific, and the Middle East & Africa.
The Hepatitis Diagnostic Test Solution market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.
The European Hepatitis Diagnostic Test Solution market has been segmented into Western Europe and Eastern Europe. Western Europe has been classified into Germany, France, the UK, Italy, Spain, and the rest of Western Europe. The Hepatitis Diagnostic Test Solution market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The Hepatitis Diagnostic Test Solution market in the Middle East & Africa has been segmented into the Middle East and Africa.
Regional Market Summary
The Americas dominated the Hepatitis Diagnostic Test Solution industry, owing to the increasing number of patients that are diagnosed with hepatitis, annually. In the Latin America and Caribbean countries, currently, around 9 million people are anti-hepatitis C virus (HCV) positive.
Europe is expected to be the second-largest region in the Hepatitis Diagnostic Test Solution industry, owing to the growing detection of hepatitis virus cases in the region.
The market in Asia-Pacific (APAC) is expected to grow significantly owing to the rising prevalence of hepatitis genotypes. Various clinical studies are being carried out. For instance, studies related to the Genotype 1b were done to understand the body’s response to the hepatitis virus.
Thus, the Hepatitis Diagnostic Test Solution market in APAC is expected to hold the third-largest share during the forecast period.
The Middle East & Africa is expected to hold the least share of the Hepatitis Diagnostic Test Solution market during the forecast due to the slow economic development, especially in Africa.
Hepatitis Diagnostic Test Solution Market Top Key Players
Some of the Key Players operating in the Hepatitis Diagnostic Test Solution Market are:
- Abbott
- Biomérieux Sa
- Bio-Rad Laboratories, Inc.
- Danaher
- DiaSorin S.p.A.
- Miraca Holdings Inc. (Fujirebio, Inc.)
- Grifols
- Onsite Lab Holding AG (MedMira, Inc.)
- Qiagen
- Roche Holding AG (Roche Diagnostics)
- Siemens (Siemens Healthineers)
- Sandoz International GmbH
Hepatitis Diagnostic Test Solution Market Segmentation
Hepatitis Diagnostic Test Solution Disease Type Outlook
- Hepatitis A
- Hepatitis B
- Hepatitis C
- Others
Hepatitis Diagnostic Test Solution Type of Technology Outlook
- Nucleic Acid Testing (NAT)
- Enzyme-Linked Immunosorbent Assay (ELISA)
- Rapid Diagnostic Tests (RDT)
- Chemiluminescence Immunoassay (CLIA)
- Genotyping
- Others
Hepatitis Diagnostic Test Solution End User Outlook
- Hospitals
- Diagnostic Laboratories
- Blood Banks
- Research institutes
- Others
Intended Audience
- Pharmaceutical companies
- Government and private laboratories
- Research and development (R&D) companies
- Research laboratories
- Market research and consulting service providers
Leading companies partner with us for data-driven Insights
Kindly complete the form below to receive a free sample of this Report
Tailored for You
- Dedicated Research on any specifics segment or region.
- Focused Research on specific players in the market.
- Custom Report based only on your requirements.
- Flexibility to add or subtract any chapter in the study.
- Historic data from 2014 and forecasts outlook till 2040.
- Flexibility of providing data/insights in formats (PDF, PPT, Excel).
- Provide cross segmentation in applicable scenario/markets.
